# US 2019/0169262 A1 · Slc45a2 peptides for immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169262 A1
- Document ID: US20190169262A1
- Status: Published application
- Kind: A1
- Application number: 15/780,597
- Filed: 2016-12-02
- Published: 2019-06-06
- Earliest claimed: 2015-12-04
- Applicants: Board of Regents, The University of Texas System
- Inventors: Gregory LIZÉE; Cassian YEE; Patrick HWU; Janos ROSZIK
- Web page: https://patentgrep.com/patent/US20190169262A1

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/00119: {Melanoma antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4272: {Melan-A/MART}
- A61K 40/4273: {Glycoprotein 100 [Gp100]}
- A61K 40/4274: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}
- A61P 35/00: Antineoplastic agents
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/876: {Skin, melanoma}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

## Claims

### Claim 1

An isolated peptide 35 amino acids in length or less and comprising the sequence of SLC45A2382-390 (SEQ ID NO:1) or SLC45A2393-402 (SEQ ID NO:2) or a sequence having at least 90% identity to SLC45A2382-390 (SEQ ID NO:1) or SLC45A2393-402 (SEQ ID NO:2), wherein the peptide selectively binds HLA-A2, HLA-A*0201, HLA-A24, or HLA-A*2402.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide is 30 amino acids in length or less.

### Claim 3 (depends on 2)

The peptide of claim 2, wherein the peptide is 25 amino acids in length or less.

### Claim 4 (depends on 3)

The peptide of claim 3, wherein the peptide is 20 amino acids in length or less.

### Claim 5 (depends on 4)

The peptide of claim 4, wherein the peptide is 15 amino acids in length or less.

### Claim 6 (depends on 1)

The peptide of claim 1, wherein the peptide comprises or consists of SLC45A2382-390 (SEQ ID NO:1) and wherein the peptide selectively binds HLA-A2 or HLA-A*0201.

### Claim 7 (depends on 6)

The peptide of claim 6, wherein the peptide comprises or consists of SLC45A2393-402 (SEQ ID NO:2) and wherein the peptide selectively binds HLA-A24 or HLA-A*2402.

### Claim 8 (depends on 1)

The peptide of claim 1, wherein the peptide is comprised in a pharmaceutical preparation.

### Claim 9 (depends on 8)

The peptide of claim 8, wherein the pharmaceutical preparation is formulated for parenteral administration, intravenous injection, intramuscular injection, inhalation, or subcutaneous injection.

### Claim 10 (depends on 9)

The peptide of claim 9, wherein the peptide is comprised in a liposome, lipid-containing nanoparticle, or in a lipid-based carrier.

### Claim 11 (depends on 10)

The peptide of claim 10, wherein the pharmaceutical preparation is formulated for injection or inhalation as a nasal spray.

### Claim 12 (depends on 1)

The peptide of claim 1, wherein the peptide is comprised in a cell culture media.

### Claim 13 (depends on 1)

A cell culture media comprising the peptide of claim 1.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the peptide of claim 1 and an excipient.

### Claim at position 15

15-33. (canceled)

### Claim 34 (depends on 1)

A method of treating a melanoma in a mammalian subject, comprising administering to the subject an effective amount of the peptide of claim 1.

### Claim at position 17

35-44. (canceled)

### Claim 45 (depends on 1)

An in vitro method for inducing a population of T cells to proliferate, comprising contacting T cells in vitro with a peptide of claim 1 in an amount sufficient to bind a HLA-A*0201 or a HLA-A2 in the T cells and promote proliferation of one or more of the T cells.

### Claim 46 (depends on 45)

The method of claim 45, wherein the T cells are cytotoxic T lymphocytes (CTL).

### Claim 47 (depends on 45)

The method of claim 45, wherein the T cells are CD8+ T cells.

### Claim 48 (depends on 45)

The method of claim 45, further comprising administering the T cells to a subject after said proliferation.

### Claim 49 (depends on 48)

The method of claim 48, wherein the subject is a human.

### Claim 50 (depends on 1)

A method of promoting an immune response in a subject against SLC45A2, comprising administering to the subject a peptide of claim 1 in an amount effective to cause proliferation of T cells that selectively target SLC45A2.

### Claim at position 24

51-58. (canceled)

### Claim 59 (depends on 1)

An isolated nucleic acid encoding the peptide of claim 1.

### Claim at position 26

60-61. (canceled)

### Claim 62 (depends on 59)

A vector comprising a contiguous sequence consisting of the nucleic acid segment of claim 59.

### Claim at position 28

63-71. (canceled)

### Claim 72 (depends on 1)

A kit comprising the peptide of claim 1 in a container.

### Claim at position 30

73-75. (canceled)